Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
This article was originally published in The Pink Sheet
Executive Summary
OTC private label giant agrees with Starboard, which owns around 6.7% of Perrigo's shares, to immediately add to Perrigo's board Starboard CEO Jeffrey Smith and two other members recommended by the hedge fund: former Pfizer CEO Jeffrey Kindler and Nestle USA executive Bradley Alford.
You may also be interested in...
Infant Formula Woes Turn Perrigo's Q2 Sour Despite Solid Americas’ OTC Sales
Perrigo reports 4% Q2 sales growth for OTC drugs in the Americas region was offset by nearly 15% drop in infant formula sale. Total consumer sales in the Americas slipped 2.5% to $582m, but CEO Murray Kessler says brighter days are ahead on benefits from Ranir oral care acquisition.
Perrigo Changes Reporting Structure In Latest Stop On Cost-Cutting Trail
Perrigo reorganizes its reporting segments to better align with its organizational structure; consumer product units are combined and renamed.
Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope
A portfolio review concluded that 'the next step to unlock shareholder value is … exploring strategic alternatives for that Tysabri royalty stream,' CEO John Hendrickson said during Perrigo's third-quarter earnings briefing.